325 related articles for article (PubMed ID: 29021477)
1. Management of Osteoporosis in Chronic Kidney Disease.
Nitta K; Yajima A; Tsuchiya K
Intern Med; 2017 Dec; 56(24):3271-3276. PubMed ID: 29021477
[TBL] [Abstract][Full Text] [Related]
2. Bisphophonates in CKD patients with low bone mineral density.
Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
[TBL] [Abstract][Full Text] [Related]
3. [The treatment of the patient presenting with chronic kidney disease (CKD) and fragility fractures].
Giusti A; Fusaro M
G Ital Nefrol; 2017 Dec; 34(Nov-Dec):. PubMed ID: 29207226
[TBL] [Abstract][Full Text] [Related]
4. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
[TBL] [Abstract][Full Text] [Related]
5. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
[TBL] [Abstract][Full Text] [Related]
6. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Wilson LM; Rebholz CM; Jirru E; Liu MC; Zhang A; Gayleard J; Chu Y; Robinson KA
Ann Intern Med; 2017 May; 166(9):649-658. PubMed ID: 28395318
[TBL] [Abstract][Full Text] [Related]
7. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
8. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
[No Abstract] [Full Text] [Related]
9. Fracture risk and treatment in chronic kidney disease.
Connelly K; Collister D; Tangri N
Curr Opin Nephrol Hypertens; 2018 May; 27(3):221-225. PubMed ID: 29547405
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
Kim JT; Kim YM; Jung KY; Choi H; Lee SY; Kim HJ
Korean J Intern Med; 2024 Jan; 39(1):148-159. PubMed ID: 38145616
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Gronskaya S; Belaya Z; Rozhinskaya L; Mamedova E; Vorontsova M; Solodovnikov A; Golounina O; Melnichenko G
Endocrine; 2023 Aug; 81(2):368-378. PubMed ID: 37133642
[TBL] [Abstract][Full Text] [Related]
15. [Is denosmab really effective and safe in the care of CKD-MBD?].
Hamano T; Nakano C
Clin Calcium; 2016 Sep; 26(9):1309-17. PubMed ID: 27561346
[TBL] [Abstract][Full Text] [Related]
16. Potential association with early changes in serum calcium level after starting or switching to denosumab combined with eldecalcitol.
Asano T; Shimizu T; Takahashi D; Ota M; Sato D; Hamano H; Hiratsuka S; Takahata M; Iwasaki N
J Bone Miner Metab; 2019 Mar; 37(2):351-357. PubMed ID: 29721807
[TBL] [Abstract][Full Text] [Related]
17. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety.
Gopaul A; Kanagalingam T; Thain J; Khan T; Cowan A; Sultan N; Clemens KK
Arch Osteoporos; 2021 Jul; 16(1):116. PubMed ID: 34319515
[TBL] [Abstract][Full Text] [Related]
18. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
19. [Bisphosphonates first-line pharmacological treatment].
Wallander M; Ljunggren Ö; Lorentzon M
Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824394
[No Abstract] [Full Text] [Related]
20. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
